PMID- 34115240
OWN - NLM
STAT- MEDLINE
DCOM- 20210816
LR  - 20210816
IS  - 1432-1335 (Electronic)
IS  - 0171-5216 (Linking)
VI  - 147
IP  - 9
DP  - 2021 Sep
TI  - The prognostic significance of PD-L1 expression on tumor and immune cells in 
      Merkel cell carcinoma.
PG  - 2569-2578
LID - 10.1007/s00432-021-03676-6 [doi]
AB  - INTRODUCTION: The aim of this study was to evaluate prognostic factors in 
      patients with non-metastatic Merkel cell carcinoma (MCC), with a particular focus 
      on immunological markers such as TILs subtyping (CD3, CD8, CD68, FoxP3, PD-L1 and 
      PD-1) and MCPyV. METHODS: Patients treated for a non-metastatic MCC with 
      oncologic surgical resection followed or not by adjuvant radiotherapy between 
      01/2007 and 12/2018 were analyzed. Local and regional control (LC, RC), distant 
      metastasis-free survival (DMFS) and overall survival (OS) were evaluated. 
      Clinical variables analyzed included age, gender, performance status, 
      comorbidity, tumor size, location and presentation type, extension, oncologic 
      resection and adjuvant radiotherapy. Pathological variables analyzed included 
      type of tumor-infiltrating lymphocytes, CD3, CD8, CD68, PD-L1 expression on 
      immune cells and tumors cells, PD-1, FoxP3 and MCPyV, assessed with 
      immunohistochemistry (IHC). RESULTS: 77 patients were included. After a median 
      follow-up of 18 months (range 0.2-144), the 1-year LC, RC, DMFS and OS were 83%, 
      60%, 82% and 75%, respectively. In multivariate analysis, a percentage of PD-L1 
      expression by immune cells >/= 1% was significantly correlated with improvement of 
      RC (p = 0.012), DMFS (p = 0.003) and OS (p = 0.006). Adjuvant radiotherapy 
      significantly improved DMFS (p = 0.021) and OS (0.041) rates. There was a 
      correlation between the presence of MCPyV + and the expression of PD-L1 on IC 
      (p = 0.05) and TC (p = 0.03). CONCLUSION: PD-L1 expression by immune and tumor 
      cells in non-metastatic MCC seems to significantly improve outcome in patients 
      who did not received PD-1/PD-L1 inhibitors. Prospective studies are needed to 
      confirm our hypothesis.
CI  - (c) 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
      part of Springer Nature.
FAU - Guenole, Morgan
AU  - Guenole M
AD  - Radiation Oncology Department, University Hospital Morvan, 2 avenue Foch, 29200, 
      Brest, France.
FAU - Benigni, Paolo
AU  - Benigni P
AD  - Department of Dermatology, University Hospital Morvan, Brest, France.
FAU - Bourbonne, Vincent
AU  - Bourbonne V
AD  - Radiation Oncology Department, University Hospital Morvan, 2 avenue Foch, 29200, 
      Brest, France.
AD  - Latim INSERM UMR 1101, UBO, Brest, France.
FAU - Lucia, Francois
AU  - Lucia F
AUID- ORCID: 0000-0001-7286-1350
AD  - Radiation Oncology Department, University Hospital Morvan, 2 avenue Foch, 29200, 
      Brest, France. francois.lucia@chu-brest.fr.
AD  - Latim INSERM UMR 1101, UBO, Brest, France. francois.lucia@chu-brest.fr.
FAU - Legoupil, Delphine
AU  - Legoupil D
AD  - Department of Pathology, University Hospital Morvan, Brest, France.
AD  - LIEN, UBO, Brest, France.
FAU - Pradier, Olivier
AU  - Pradier O
AD  - Radiation Oncology Department, University Hospital Morvan, 2 avenue Foch, 29200, 
      Brest, France.
AD  - Latim INSERM UMR 1101, UBO, Brest, France.
FAU - Misery, Laurent
AU  - Misery L
AD  - Department of Pathology, University Hospital Morvan, Brest, France.
AD  - LIEN, UBO, Brest, France.
FAU - Uguen, Arnaud
AU  - Uguen A
AD  - Department of Dermatology, University Hospital Morvan, Brest, France.
FAU - Schick, Ulrike
AU  - Schick U
AD  - Radiation Oncology Department, University Hospital Morvan, 2 avenue Foch, 29200, 
      Brest, France.
AD  - Latim INSERM UMR 1101, UBO, Brest, France.
LA  - eng
PT  - Journal Article
DEP - 20210611
PL  - Germany
TA  - J Cancer Res Clin Oncol
JT  - Journal of cancer research and clinical oncology
JID - 7902060
RN  - 0 (B7-H1 Antigen)
RN  - 0 (CD274 protein, human)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - B7-H1 Antigen/*metabolism
MH  - Carcinoma, Merkel Cell/immunology/metabolism/*pathology/therapy
MH  - Combined Modality Therapy
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Lymphocytes, Tumor-Infiltrating/*immunology
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Retrospective Studies
MH  - Skin Neoplasms/immunology/metabolism/*pathology/therapy
MH  - Survival Rate
OTO - NOTNLM
OT  - Immunological markers
OT  - Merkel cell carcinoma
OT  - PD-L1 expression
OT  - Prognostic
EDAT- 2021/06/12 06:00
MHDA- 2021/08/17 06:00
CRDT- 2021/06/11 12:25
PHST- 2020/12/23 00:00 [received]
PHST- 2021/05/27 00:00 [accepted]
PHST- 2021/06/12 06:00 [pubmed]
PHST- 2021/08/17 06:00 [medline]
PHST- 2021/06/11 12:25 [entrez]
AID - 10.1007/s00432-021-03676-6 [pii]
AID - 10.1007/s00432-021-03676-6 [doi]
PST - ppublish
SO  - J Cancer Res Clin Oncol. 2021 Sep;147(9):2569-2578. doi: 
      10.1007/s00432-021-03676-6. Epub 2021 Jun 11.